

In any event, the use of clinical indexes and high-sensitivity troponin does not completely eliminate the need for functional or anatomical tests to detect coronary disease in a part of the population referred to a chest pain unit, and in our opinion, none of the factors mentioned affects the validity of the results of our study.

Miriam Piñeiro-Portela,^{a,b,*} Jesús Peteiro-Vázquez,^{a,b}
Alberto Bouzas-Mosquera,^{a,b}
and José Manuel Vázquez-Rodríguez^{a,b}

^aServicio de Cardiología, Unidad de Imagen y Pruebas Funcionales, Hospital Universitario de A Coruña, A Coruña, Spain

^bCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain

* Corresponding author:

E-mail address: Miriam.Pineiro.Portela@sergas.es
(M. Piñeiro-Portela).

Available online 10 August 2020

REFERENCES

1. Bouzas-Mosquera A, Peteiro J, Broullón FJ, et al. A clinical score to obviate the need for cardiac stress testing in patients with acute chest pain and negative troponins. *Am J Emerg Med.* 2016;34:1421–1426.
2. Bouzas-Mosquera A, Peteiro J, Broullón FJ, et al. Troponin levels within the normal range and probability of inducible myocardial ischemia and coronary events in patients with acute chest pain. *Eur J Intern Med.* 2016;28:59–64.
3. Bouzas-Mosquera A, Peteiro J, Broullón FJ, et al. Temporal changes in the use and results of exercise echocardiography. *Eur Heart J Cardiovasc Imaging.* 2015;16:1207–1212.

<https://doi.org/10.1016/j.rec.2020.06.025>
1885-5857/

© 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

The use of antiplatelet agents for arterial thromboprophylaxis in COVID-19



El uso de agentes antiplaquetarios para la tromboprofilaxis arterial en la COVID-19

To the Editor,

We read with interest the retrospective study reported by Rey et al.¹ to describe the clinical characteristics and outcomes of patients with novel coronavirus disease 2019 (COVID-19) who developed acute arterial thrombosis. Despite being a small-scale study (n = 87), there are a few clinical trends to be noted. Based on the reported findings, we observed that the proportion of COVID-19 patients with major cardiovascular risk factors who developed acute arterial thrombosis is higher than that of their non-COVID-19 counterparts. Such finding hinted at the possibility that thromboinflammation plays a greater role for the development of arterial thrombosis in COVID-19 patients than traditional cardiovascular risk factors. In addition, the mortality rate of COVID-19 patients with arterial thrombosis was high (44.7%), which indicates a poor prognosis. Therefore, we would like to propose routine antiplatelet therapy (low-dose aspirin, clopidogrel, ticagrelor, prasugrel, ticlopidine, and dipyridamole) for arterial thromboprophylaxis in COVID-19 patients who are deemed at heightened risk for the development of acute arterial thrombosis.

Low-dose aspirin (75–150 mg/d) is sufficient to irreversibly acetylate Ser 530 of COX-1, thus preferentially inhibiting platelet generation of thromboxane A₂, and interfering with the formation of arterial thrombus. On the other hand, for P2Y₁₂ inhibitors (clopidogrel, ticagrelor, prasugrel, and ticlopidine), either the parent drug or the active metabolite blocks the P2Y₁₂ component of adenosine diphosphate receptors on the platelet surface, which prevents activation of the glycoprotein IIb/IIIa receptor complex, thereby reducing platelet aggregation and subsequent arterial thrombus formation. Dipyridamole inhibits the activity of adenosine deaminase and phosphodiesterase, which causes an accumu-

lation of adenosine, adenine nucleotides, and cyclic AMP; these mediators then inhibit platelet aggregation and the subsequent arterial thrombus formation. Aspirin and dipyridamole may be particularly favored in COVID-19 patients; aspirin possesses antiviral activity related to its ability to inhibit the coronavirus-induced nuclear factor kappa B pathway,² while dipyridamole appears to directly suppress severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of COVID-19 based on in silico docking analysis and in vitro cell culture study.³

There have been limited studies that have demonstrated favorable clinical outcomes in COVID-19 with the use of antiplatelet therapy either alone or in combination with an anticoagulant. In their prospective observational study among critically ill patients with COVID-19, Ranucci et al.⁴ reported that a combination of an enhanced prophylactic dose of heparin, clopidogrel, and antithrombin correction returned the parameters of viscoelastic coagulation tests to essentially normal (129). In a proof-of-concept, case control, phase IIb study in 5 patients with COVID-19 and severe respiratory failure treated with a combination of tirofiban, aspirin, clopidogrel, and fondaparinux, Viecca et al.⁵ reported superiority in terms of improvement in oxygenation, and weaning time from continuous positive airway pressure therapy compared with controls matched for disease severity who received either prophylactic or treatment-dose heparin. Liu et al.³ performed a multicenter, parallel, randomized controlled trial of 31 patients with COVID-19 with severe or critical illness, who received either standard of care (n = 17) or dipyridamole at a dose of 50 mg 3 times daily for 14 days in addition to the standard of care (n = 14). Patients randomized to dipyridamole had an increased survival and remission rate that approached statistical significance (odds ratio, 23.75; 95% confidence interval, 0.87–648; P = .06), as well as reduced D-dimer levels, and increased lymphocyte and platelet counts.

Nevertheless, at the time of writing, we are not aware of any studies that have reported the outcomes on the use of antiplatelet agents for the prevention of arterial thrombotic events in patients with COVID-19. We urge the performance of a study to evaluate the use of antiplatelet therapy to prevent arterial thrombotic events,

SEE RELATED CONTENT:

<https://doi.org/10.1016/j.rec.2020.05.008>

<https://doi.org/10.1016/j.rec.2020.09.020>

which can be fatal in patients with COVID-19. In the meantime, antiplatelet therapy can be prudently administered to critically ill patients with COVID-19 who are at high risk of thromboinflammation but low risk of bleeding. With more studies available in the future, we could then identify the population of patients with COVID-19 most likely to benefit from the use of antiplatelet therapy to prevent the occurrence of arterial or even venous thrombotic events.

Chia Siang Kow^{a,*} and Syed Shahzad Hasan^b

^aSchool of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia

^bDepartment of Pharmacy, University of Huddersfield, Huddersfield, United Kingdom

*Corresponding author:

E-mail address: chiasiang_93@hotmail.com (C.S. Kow).

Available online 28 August 2020

REFERENCES

1. Rey JR, Caro-Codón J, Poveda Pineda D, et al. Arterial thrombotic complications in hospitalized patients with COVID-19. *Rev Esp Cardiol.* 2020;73:769–771.
2. Müller C, Karl N, Ziebuhr J, Pleschka S. Dipyridamole and aspirin acetylsalicylate impairs coronavirus replication. *J Antivir Antiretrovir.* 2016;8:142–150.
3. Liu X, Li Z, Liu S, et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19 [published online ahead of print, 2020 Apr 20]. *Acta Pharm Sin B.* 2020. <http://doi.org/10.1016/j.apsb.2020.04.008>.
4. Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. *J Thromb Haemost.* 2020;18:1747–1751.
5. Viecca M, Radovanovic D, Forleo GB, Santus P. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study. *Pharmacol Res.* 2020;158:104950.

<https://doi.org/10.1016/j.rec.2020.08.009>
1885-5857/

© 2020 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

A new inflammatory-microthrombotic syndrome as an explanation for thrombotic complications in patients with COVID-19



Un nuevo síndrome inflamatorio-microtrombótico como explicación para las complicaciones trombóticas en pacientes con COVID-19

To the Editor,

We have read with great interest the article by King et al.¹ recently published in *Revista Española de Cardiología*. In this article, the authors discuss the higher incidence of thrombotic events in multiple territories and a higher International Society on Thrombosis and Haemostasis (ISTH) disseminated intravascular coagulation (DIC) score in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although the authors mention that they have not ruled out a pre-existing prothrombotic state, our group, consistent with what the authors described,² has proposed a possible role of endothelial injury, complement, and coagulation in the pathogenesis of coronavirus disease 2019 (COVID-19).³

Our pathogenic scheme is based on the similarity of certain clinical and histopathologic findings of various entities that have thrombotic microangiopathy in common with COVID-19, and it postulates that the damage induced by this disease has an endothelial origin with 2 pathogenic routes: an inflammatory route, with predominance of the “cytokine storm” component, and a microangiopathic route involving the complement system.³

Furthermore, endothelial involvement could lead to platelet activation, thus altering coagulation and causing DIC, as described by the authors of the article. This fact *per se* could increase thrombin and prothrombin and trigger complement activation through C5.⁴

For instance, thrombotic microangiopathy has been reported in a patient with severe COVID-19, indicating a pathogenic relationship between these conditions.⁵ The potential role of ADAMTS13 deficiency in serious forms of the disease is another possible factor, as described by Huisman et al.⁶ in a recent article.

Additionally, the inflammatory route itself could activate complement through certain neutrophil serine proteases and macrophages.⁷ Consequently, we believe that there is a strong relationship between inflammation, complement, thrombotic microangiopathy, and coagulation in the pathogenesis of COVID-19. This may represent a new COVID-19–related inflammatory-microthrombotic syndrome which could explain the authors’ interesting findings.^{2–4}

Francisco Valga,^{a,*} Nicanor Vega-Díaz,^a Manuel Macía,^b and José Carlos Rodríguez-Pérez^a

^aServicio de Nefrología, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas, Spain

^bServicio de Nefrología, Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain

*Corresponding author:

E-mail address: fvalga@hotmail.com (F. Valga).

Available online 2 October 2020

REFERENCES

1. Rey JR, Caro-Codón J, Poveda D, Merino JL, Iniesta AM, López-Sendón JL. Complicaciones arteriales trombóticas en pacientes hospitalizados con COVID-19. *Rev Esp Cardiol.* 2020;73:769–771.
2. Noris M, Benigni A, Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. *Kidney Int.* 2020;98:314–322.
3. Valga F, Vega-Díaz N, Macía M, Monzón T, Rodríguez-Pérez JC. Targeting complement in severe coronavirus disease 2019 to address microthrombosis. *Clin Kidney J.* 2020;13:477–479.
4. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. *Nat Med.* 2006;12:682–687.
5. Jhaveri KD, Meir LR, Flores Chang BS, et al. Thrombotic microangiopathy in a patient with COVID-19. *Kidney Int.* 2020;98:509–512.

SEE RELATED CONTENT:

<https://doi.org/10.1016/j.rec.2020.05.008>

<https://doi.org/10.1016/j.rec.2020.09.020>